| First Author | Yamada D | Year | 2016 |
| Journal | Biochem Biophys Res Commun | Volume | 476 |
| Issue | 4 | Pages | 475-480 |
| PubMed ID | 27246732 | Mgi Jnum | J:236035 |
| Mgi Id | MGI:5804489 | Doi | 10.1016/j.bbrc.2016.05.147 |
| Citation | Yamada D, et al. (2016) mTORC1 is a critical mediator of oncogenic Semaphorin3A signaling. Biochem Biophys Res Commun 476(4):475-80 |
| abstractText | Aberration of signaling pathways by genetic mutations or alterations in the surrounding tissue environments can result in tumor development or metastasis. However, signaling molecules responsible for these processes have not been completely elucidated. Here, we used mouse Lewis lung carcinoma cells (LLC) to explore the mechanism by which the oncogenic activity of Semaphorin3A (Sema3A) signaling is regulated. Sema3A knockdown by shRNA did not affect apoptosis, but decreased cell proliferation in LLCs; both the mammalian target of rapamycin complex 1 (mTORC1) level and glycolytic activity were also decreased. In addition, Sema3A knockdown sensitized cells to inhibition of oxidative phosphorylation by oligomycin, but conferred resistance to decreased cell viability induced by glucose starvation. Furthermore, recombinant SEMA3A rescued the attenuation of cell proliferation and glycolytic activity in LLCs after Sema3A knockdown, whereas mTORC1 inhibition by rapamycin completely counteracted this effect. These results demonstrate that Sema3A signaling exerts its oncogenic effect by promoting an mTORC1-mediated metabolic shift from oxidative phosphorylation to aerobic glycolysis. |
